GLP-1 Comparison

Introduction If you are considering medical treatment for obesity in 2026, two names dominate the conversation: Mounjaro (tirzepatide) and Wegovy (semaglutide). Both are once-weekly injectable medications that have transformed the landscape of weight management, producing results that were previously achievable only with bariatric surgery. But they are not interchangeable — they differ in their mechanism of action, the magnitude of weight loss they produce, their side effect profiles, their cardiovascular evidence base, and their cost. ...

Introduction Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. The choice between GLP-1 medications requires individualized assessment by a qualified healthcare provider. The two heavyweight champions of GLP-1 weight loss — Ozempic (semaglutide) and Mounjaro (tirzepatide) — dominate the conversation in 2026. But the weight loss injectables landscape now includes several options: liraglutide (Saxenda, an older daily GLP-1), semaglutide (Ozempic/Wegovy, weekly), and tirzepatide (Mounjaro/Zepbound, weekly dual-agonist). Which one should you choose? ...